FAS and neoplasm: Future work should address how CD95-induced senescence shapes the growth of such tumors and their response to therapy, whether the growth of other tumor (sub-) types may be regulated by CD95-induced senescence, and whether senescence-inducing therapy has value in the treatment of metastasized (aggressive) CMS1 tumors.